Podcasts about psychiatry and mental health

  • 44PODCASTS
  • 989EPISODES
  • 48mAVG DURATION
  • ?INFREQUENT EPISODES
  • May 30, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about psychiatry and mental health

Show all podcasts related to psychiatry and mental health

Latest podcast episodes about psychiatry and mental health

Conference Coverage
Digital CBT and Pulmonary Fibrosis: Addressing Anxiety and Quality of Life

Conference Coverage

Play Episode Listen Later May 30, 2025


Guest: Jessica Shull, PhD Guest: Joshua Solomon, MD Host: Ryan Quigley Patients with pulmonary fibrosis often face anxiety and emotional distress that go unadressed during their care. Given this unmet need, a digital cognitive behavioral therapy (CBT) platform was designed to support emotional wellbeing alonside medical treatment. Mr. Ryan Quigley sits down with Drs. Jessica Shull and Joshua Solomon, who presented at the 2025 American Thoracic Society International Conference to explore how this platform may enhance quality of life, support therapy adherence, and integrate into routine care. Dr. Shull is the Director of Digital Health and a Clinical Science Liaison at Vicore Pharma, and Dr. Solomon is a Professor of Medicine in Pulmonary Care and the Director of the Interstitial Lung Disease Program at National Jewish Health.

NeuroFrontiers
Understanding Schizophrenia: New Insights on Prevalence, Treatment, and Quality of Life

NeuroFrontiers

Play Episode Listen Later Feb 18, 2025


Guest: Natalie Bareis, PhD, LMSW A recent study on schizophrenia uncovered a significantly higher prevalence than previously estimated. The study also highlights ongoing struggles for patients, including low employment rates, poor general functioning, and limited access to adequate treatment. Join lead author Dr. Natalie Bareis as she discusses these findings and highlights the need for better policies and treatment accessibility. Dr. Bareis is an Assistant Professor of Clinical Behavioral Medicine in Psychiatry at Columbia University.

NeuroFrontiers
Gaps in Schizophrenia Spectrum Disorders Care: A Look at Causes and Solutions

NeuroFrontiers

Play Episode Listen Later Feb 18, 2025


Guest: Natalie Bareis, PhD, LMSW Despite the availability of effective treatments for schizophrenia spectrum disorders, many patients are not receiving minimally adequate care based on a recent study. Tune in to hear Dr. Natalie Bareis discuss barriers to care, including the impact of substance use disorders and the limited availability of specialized programs, as well as how we can improve access and outcomes for patients with schizophrenia spectrum disorders. Dr. Bareis is an Assistant Professor of Clinical Behavioral Medicine in Psychiatry at Columbia University.

ReachMD CME
The Safety of Sodium Oxybate in Treating Narcolepsy

ReachMD CME

Play Episode Listen Later Jan 31, 2025


CME credits: 0.50 Valid until: 31-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-safety-of-sodium-oxybate-in-treating-narcolepsy/29457/ Sodium content and the disruption associated with the twice-nightly dosing of sodium oxybate are common concerns when treating patients with narcolepsy. Is sodium content truly a risk factor for cardiovascular sequelae in patients with narcolepsy? Does twice-nightly dosing lead to medically unacceptable dosing errors? Join Drs. Sally Ibrahim and Clete Kushida as they dive into these questions and provide actionable answers for you to use in your clinical practice.=

Penn Undergraduate Biotech Society (PUBS) Podcast
Rewiring the Mind: Dr. Balderston on TMS, Psychiatry, and Mental Health

Penn Undergraduate Biotech Society (PUBS) Podcast

Play Episode Listen Later Jan 31, 2025 78:15


In this episode, Jason Fang, an undergraduate at the University of Pennsylvania, sits down with Dr. Nicholas Balderston, Assistant Professor of Psychiatry at the Perelman School of Medicine, to explore the science behind Transcranial Magnetic Stimulation (TMS) and its role in modern psychiatry. Dr. Balderston talks about his career path, from his early research interests to his ongoing work studying brain stimulation and anxiety disorders. They discuss how TMS compares to traditional treatments, the evolving landscape of psychiatric research, and what it could mean for the future of mental health care.

Medical Industry Feature
Digital Therapeutics Clinical Trials: From Design to Data Interpretation

Medical Industry Feature

Play Episode Listen Later Nov 22, 2024


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sarah Shizuko Morimoto, PsyD Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it's important to evaluate the supporting evidence when considering digital therapeutics for mental health.1 Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City. Reference: American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model Dr. Morimoto is a paid consultant of Otsuka. November 2024 US.UNB.X.24.00100

Medical Industry Feature
The Evolution of Psychiatric Healthcare: Integrating Digital Therapeutics into Practice

Medical Industry Feature

Play Episode Listen Later Nov 4, 2024


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Robert McCarron, MD Guest: Arwen Podesta, MD Digital therapeutics are a relatively new and intriguing treatment option in mental health care but translating them from a clinical trial to clinical practice can be challenging. That's why Drs. Robert McCarron and Arwen Podesta join Dr. Charles Turck to share strategies for incorporating digital therapeutics into clinical practice. Dr. McCarron is a Professor in the Department of Psychiatry and Human Behavior at the University of California, Irvine School of Medicine, and Dr. Podesta is the President of the Louisiana Psychiatric Medical Association. Drs. McCarron and Podesta are consultants for Otsuka. September 2024 US.UNB.X.24.00073

Medical Industry Feature
Engaging Patients and Caregivers About Digital Therapeutics

Medical Industry Feature

Play Episode Listen Later Oct 31, 2024


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Maggie Emerson, DNP, APRN, PMHNP-BC Guiding patients and caregivers through the fast-moving landscape of digital therapeutics can be a challenging but worthwhile part of providing effective and accessible care. That's why Dr. Charles Turck speaks with Dr. Maggie Emerson about partnering with patients and caregivers around this relatively new treatment in mental health care. Dr. Emerson is a Clinical Associate Professor at the University of Nebraska Medical Center College of Nursing in Omaha. Dr. Emerson is a paid consultant of Otsuka. September 2024 US.UNB.X.24.00082

Advances in Women's Health
Screening for Postpartum Depression: A Guideline-Based Discussion

Advances in Women's Health

Play Episode Listen Later Oct 23, 2024


Host: Matt Birnholz, MD Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed.1-4 To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Bauman BL, Ko JY, Cox S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(19):575-581. Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes. J Clin Psychiatry. 2016;77(9):1189-1200. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. …

Advances in Women's Health
Expert Insights and Clinical Strategies for Postpartum Depression Screening

Advances in Women's Health

Play Episode Listen Later Oct 23, 2024


Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner.1-4 Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Campbell SB, Cohn JF, Meyers T. Depression in First-Time Mothers: Mother-Infant Interaction and Depression Chronicity. Dev Psychol. 1995;31:349-357. Moore Simas TA, Huang MY, Patton C, et al. The humanistic burden of postpartum depression: a systematic literature review. Curr Med Res Opin. 2019;35(3):383-393. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. Sage Therapeutics and the Sage Therapeutics logo …

Medical Industry Feature
Expert Insights and Clinical Strategies for Postpartum Depression Screening

Medical Industry Feature

Play Episode Listen Later Oct 23, 2024


Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Since postpartum depression is a serious medical condition that can negatively impact mothers, infants, and partners, it is important to identify symptoms in a timely manner.1-4 Dr. Jennifer Payne and Dr. Melissa Simon are here to share their clinical experiences screening patients for postpartum depression, explore strategies to overcome common challenges in screening, and identify best practices for collaborating in the care of perinatal women. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Campbell SB, Cohn JF, Meyers T. Depression in First-Time Mothers: Mother-Infant Interaction and Depression Chronicity. Dev Psychol. 1995;31:349-357. Moore Simas TA, Huang MY, Patton C, et al. The humanistic burden of postpartum depression: a systematic literature review. Curr Med Res Opin. 2019;35(3):383-393. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. Sage Therapeutics and the Sage Therapeutics logo …

Medical Industry Feature
Screening for Postpartum Depression: A Guideline-Based Discussion

Medical Industry Feature

Play Episode Listen Later Oct 23, 2024


Host: Matt Birnholz, MD Guest: Jennifer L. Payne, MD Guest: Melissa Simon, MD Postpartum depression is a serious medical condition that is among the most common complications during and after pregnancy; however, it is often underdiagnosed.1-4 To learn more about screening patients for postpartum depression, Dr. Matt Birnholz speaks with Dr. Jennifer Payne and Dr. Melissa Simon about screening strategies, the impact of health inequities, and the latest medical guidelines regarding the importance of early screening for postpartum depression. Dr. Payne is a Professor of Psychiatry and Neurobehavioral Sciences as well as Obstetrics and Gynecology at the University of Virginia, and Dr. Simon is a Professor of Obstetrics and Gynecology at the Northwestern University Feinberg School of Medicine. References American Psychiatric Association. Depressive disorders. In: American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5™. 5th ed. American Psychiatric Publishing; 2013:155-188. Bauman BL, Ko JY, Cox S, et al. Vital Signs: Postpartum Depressive Symptoms and Provider Discussions About Perinatal Depression - United States, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(19):575-581. Cox EQ, Sowa NA, Meltzer-Brody SE, Gaynes BN. The Perinatal Depression Treatment Cascade: Baby Steps Toward Improving Outcomes. J Clin Psychiatry. 2016;77(9):1189-1200. Thompson KS, Fox JE. Post-partum depression: a comprehensive approach to evaluation and treatment. Ment Health Fam Med. 2010;7(4):249-257. …

GI Insights
Recognizing and Addressing Burnout Among GI Providers

GI Insights

Play Episode Listen Later Oct 18, 2024


Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Brian E. Lacy, MD, PhD About 50 percent of gastrointestinal providers are experiencing some degree of burnout, which can lead to a variety of personal and professional challenges. Joining Dr. Peter Buch to discuss the signs of burnout and what you can do to mitigate them is Dr. Brian Lacy, lead author of the “Burnout in Gastrointestinal Providers” article published in the American Journal of Gastroenterology in 2024.

ReachMD CME
Inconsistent Outcomes: How Ignoring Guidelines Leads to Unpredictable Results

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/inconsistent-outcomes-how-ignoring-guidelines-leads-to-unpredictable-results/28624/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Proactively Uncovering Potential Traumatic Experiences Linked to Patient Psychiatric Symptoms in Women

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/proactively-uncovering-potential-traumatic-experiences-linked-to-patient-psychiatric-symptoms-in-women/28622/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Role of PCP & Ob-Gyn With Women at Risk for PTSD: Recognition, Screening, and Referral

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/role-of-pcp-ob-gyn-with-women-at-risk-for-ptsd-recognition-screening-and-referral/28621/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Prevalence and Burden of PTSD in Women: Focus on Factors That Affect Patient Presentation, Such as Race, Risk Factors, Stigma, and Other Drivers

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/prevalence-and-burden-of-ptsd-in-women-focus-on-factors-that-affect-patient-presentation-such-as-race-risk-factors-stigma-and-other-drivers/28620/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Setting the Stage: Unmet Needs in the Treatment of Women With PTSD

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-stage-unmet-needs-in-the-treatment-of-women-with-ptsd/28618/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Limitations of Current Treatments: FDA-Approved and Off-Label Approaches

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/limitations-of-current-treatments-fda-approved-and-off-label-approaches/28625/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Pathophysiology and Pharmacologic Rationale of Emerging Agents for the Treatment of PTSD

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/pathophysiology-and-pharmacologic-rationale-of-emerging-agents-for-the-treatment-of-ptsd/28626/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Profile and Role of Emerging Treatment Options: MOA, Safety and Efficacy, and Identifying the Patients Who May Benefit

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/profile-and-role-of-emerging-treatment-options-moa-safety-and-efficacy-and-identifying-the-patients-who-may-benefit/28627/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Modeling Activity: Quality Conversations With Patients About Suboptimal Management of PTSD Symptoms and Emerging Treatment Options

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/modeling-activity-quality-conversations-with-patients-about-suboptimal-management-of-ptsd-symptoms-and-emerging-treatment-options/28647/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
Conversations With Patients About PTSD, Screening, and Referral

ReachMD CME

Play Episode Listen Later Oct 15, 2024


CME credits: 1.00 Valid until: 15-10-2025 Claim your CME credit at https://reachmd.com/programs/cme/conversations-with-patients-about-ptsd-screening-and-referral/28623/ Patients with PTSD suffer from a range of psychiatric symptoms that severely reduce their quality of life. PTSD has proven to not only be a complicated diagnosis, but also one that has a low index of suspicion. Many patients are not screened for PTSD, and those who are diagnosed often gain little benefit from currently available treatments. Join us as these issues are dissected by Drs. Joseph Goldberg and Roger McIntyre, with the objective of providing clinicians with key action steps to take to improve outcomes for patients affected by PTSD.

ReachMD CME
The Art of Adherence: Clinician Strategies for Enhancing Medication Compliance

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-art-of-adherence-clinician-strategies-for-enhancing-medication-compliance/26468/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

ReachMD CME
Empowering Patients: Enhancing Engagement for Better MDD Outcomes

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/empowering-patients-enhancing-engagement-for-better-mdd-outcomes/26467/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

ReachMD CME
Beyond Monotherapy: Augmentation Strategies to Combat the Residual Symptoms of MDD

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/beyond-monotherapy-augmentation-strategies-to-combat-the-residual-symptoms-of-mdd/26466/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

ReachMD CME
Advancing Care: Innovative Therapies for Residual Symptoms in MDD

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/advancing-care-innovative-therapies-for-residual-symptoms-in-mdd/26465/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

ReachMD CME
Navigating Traditional Treatment Options: Current Therapeutic Strategies and Their Limitations for Residual Symptoms in MDD

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/navigating-traditional-treatment-options-current-therapeutic-strategies-and-their-limitations-for-residual-symptoms-in-mdd/26464/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

ReachMD CME
Personalized Care: Tailoring Treatment Plans for Residual Symptoms in MDD

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/personalized-care-tailoring-treatment-plans-for-residual-symptoms-in-mdd/26463/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

ReachMD CME
Diagnostic Hurdles: Recognizing and Addressing Treatment-Resistant Depression

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-hurdles-recognizing-and-addressing-treatment-resistant-depression/26462/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

ReachMD CME
Hidden in Plain Sight: Overlapping Symptoms That Challenge a Diagnosis of MDD

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/hidden-in-plain-sight-overlapping-symptoms-that-challenge-a-diagnosis-of-mdd/26461/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

ReachMD CME
Beneath the Surface: Understanding the Pathophysiology of Residual MDD Symptoms

ReachMD CME

Play Episode Listen Later Jul 15, 2024


CME credits: 1.00 Valid until: 15-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/understanding-the-pathophysiology-of-residual-mdd-symptoms/26459/ This series of bite-sized episodes contains important information on identifying and treating residual symptoms in major depressive disorder (MDD). Drs. Joseph Goldberg and Manpreet Kaur Singh discuss best practices for recognizing early symptoms, reaching a diagnosis, and treating residual symptoms in patients with MDD.

Advances in Women's Health
Importance of a Timely Postpartum Depression Diagnosis: Patient Perspectives

Advances in Women's Health

Play Episode Listen Later Jul 8, 2024


Host: Matt Birnholz, MD Guest: Kay Matthews, LCHW Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with postpartum depression, barriers that can prevent or delay patients from seeking care, and strategies for combatting stigma and ensuring a timely diagnosis. Sage Therapeutics and the Sage Therapeutics logo are registered trademarks of Sage Therapeutics, Inc.Sage Therapeutics, Inc. All rights reserved.Sage Therapeutics ©2024 MRC-PPD-00792 06/2024

Medical Industry Feature
Importance of a Timely Postpartum Depression Diagnosis: Patient Perspectives

Medical Industry Feature

Play Episode Listen Later Jul 8, 2024


Host: Matt Birnholz, MD Guest: Kay Matthews, LCHW Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with postpartum depression, barriers that can prevent or delay patients from seeking care, and strategies for combatting stigma and ensuring a timely diagnosis. Sage Therapeutics and the Sage Therapeutics logo are registered trademarks of Sage Therapeutics, Inc.Sage Therapeutics, Inc. All rights reserved.Sage Therapeutics ©2024 MRC-PPD-00792 06/2024

Medical Industry Feature
Importance of a Timely Postpartum Depression Diagnosis: Patient Perspectives

Medical Industry Feature

Play Episode Listen Later Jul 8, 2024


Host: Matt Birnholz, MD Guest: Kay Matthews, LCHW Ms. Kay Matthews has lived experience with postpartum depression and now advocates for others as the Executive Director and Founder of Shades of Blue, which is dedicated to breaking cultural barriers in maternal mental health. Tune in to hear her speak with Dr. Matt Birnholz about her journey with postpartum depression, barriers that can prevent or delay patients from seeking care, and strategies for combatting stigma and ensuring a timely diagnosis. Sage Therapeutics and the Sage Therapeutics logo are registered trademarks of Sage Therapeutics, Inc.Sage Therapeutics, Inc. All rights reserved.Sage Therapeutics ©2024 MRC-PPD-00792 06/2024

ReachMD CME
Case Study: What Do Augmentation and Switching Strategies Look Like in Real-World Clinical Practice?

ReachMD CME

Play Episode Listen Later Jun 28, 2024


CME credits: 1.25 Valid until: 28-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/case-study-what-do-augmentation-and-switching-strategies-look-like-in-real-world-clinical-practice/26599/ Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

ReachMD CME
D2 Antagonists Limitations and Challenges: A New Era in Schizophrenia Pathophysiology

ReachMD CME

Play Episode Listen Later Jun 28, 2024


CME credits: 1.25 Valid until: 28-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/d2-antagonists-limitations-and-challenges-a-new-era-in-schizophrenia-pathophysiology/26600/ Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

ReachMD CME
Stratified Care: The Role of Switching or Augmentation Therapies Used When Treating Schizophrenia

ReachMD CME

Play Episode Listen Later Jun 28, 2024


CME credits: 1.25 Valid until: 28-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/26601/ Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

ReachMD CME
Exploring the Spectrum of Efficacy in Emerging Schizophrenia Therapies: From Positive to Negative to Cognitive Symptoms

ReachMD CME

Play Episode Listen Later Jun 28, 2024


CME credits: 1.25 Valid until: 28-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/exploring-the-spectrum-of-efficacy-in-emerging-schizophrenia-therapies-from-positive-to-negative-to-cognitive-symptoms/26602/ Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

ReachMD CME
From Trial to Treatment: Translating Emerging Clinical Data into Meaningful Schizophrenia Clinical Care

ReachMD CME

Play Episode Listen Later Jun 28, 2024


CME credits: 1.25 Valid until: 28-06-2025 Claim your CME credit at https://reachmd.com/programs/cme/from-trial-to-treatment-translating-emerging-clinical-data-into-meaningful-schizophrenia-clinical-care/26603/ Despite the advances that have been made with atypical antipsychotics indicated for the treatment of schizophrenia (SCZ), significant safety and efficacy concerns persist with these D2 blockers. Inadequate response to these treatments is common. Several emerging agents are undergoing phase 3 clinical trials. These new treatments possess unique mechanisms of action, encouraging efficacy profiles across positive, negative, and cognitive domains and favorable safety profiles that offer new hope for those living with SCZ. This educational series will cover accurately identifying individuals, including those in unique patient populations, who may benefit from switching to or augmentation with an emerging treatment option, how and when to incorporate switching or augmentation strategies, and how to integrate new therapies into current clinical practice.

ReachMD CME
Glycine's Role in Driving the Cognitive Symptoms of CIAS

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/glycines-role-in-driving-the-cognitive-symptoms-of-cias/20292/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
Not All Therapy Needs to Be Swallowed or Injected: The Future of Digital Therapeutics to Alleviate the Negative Symptoms of Schizophrenia

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/not-all-therapy-needs-to-be-swallowed-or-injected-the-future-of-digital-therapeutics-to-alleviate-the-negative-symptoms-of-schizophrenia/20300/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
Integration Is the Key to Success: How Will the New SCZ Therapies Fit Into Clinical Treatment Paradigms?

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/integration-is-the-key-to-success-how-will-the-new-scz-therapies-fit-into-clinical-treatment-paradigms/20299/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
Staying Current: What Do Recent Clinical Trial Data Say About the New and Emerging Treatment Options for CIAS?

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/staying-current-what-do-recent-clinical-trial-data-say-about-the-new-and-emerging-treatment-options-for-cias/20298/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
Limitations of the Current Therapeutics Used to Manage CIAS

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/20297/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
How do you apply cognitive remediation in CIAS?

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/challenges-of-integrating-cognitive-remediation-in-cias/20296/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
Tools of the Trade: Measurement-Based Care for CIAS

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/tools-of-the-trade-measurement-based-care-for-cias/20295/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
Unraveling the Overlapping Negative and Cognitive Symptoms in Schizophrenia

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/unraveling-the-overlapping-negative-and-cognitive-symptoms-in-schizophrenia/20294/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
CIAS Effects on Patients and Caregivers: What Is the Personal and Economic Burden Caused by CIAS?

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/cias-effects-on-patients-and-caregivers-what-is-the-personal-and-economic-burden-caused-by-cias/20293/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.

ReachMD CME
Understanding CIAS: What Does Current Literature Say About the Etiology and Pathophysiology of CIAS?

ReachMD CME

Play Episode Listen Later Apr 30, 2024


CME credits: 1.00 Valid until: 30-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/understanding-cias-what-does-current-literature-say-about-the-etiology-and-pathophysiology-of-cias/20291/ This series of bite-sized episodes will provide important information on cognitive impairment associated with schizophrenia. Drs. Philip Harvey and Martin Strassnig discuss the pathophysiology, diagnosis, and emerging therapies to treat cognitive impairment associated with schizophrenia.